Next Article in Journal
Effectiveness of Teeth Whitening after Regenerative Endodontics Procedures: An In Vitro Study
Previous Article in Journal
Factors Associated with Mortality in Coronavirus-Associated Mucormycosis: Results from Mycotic Infections in COVID-19 (MUNCO) Online Registry
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

The Safety and Impact of Raising the Urine Culture Reporting Threshold in Hospitalized Patients

Infectious Disease Institute, Internal Medicine Division, Soroka Medical Center, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheba 84101, Israel
*
Author to whom correspondence should be addressed.
J. Clin. Med. 2022, 11(23), 7014; https://doi.org/10.3390/jcm11237014
Submission received: 21 September 2022 / Revised: 21 November 2022 / Accepted: 25 November 2022 / Published: 27 November 2022
(This article belongs to the Section Nephrology & Urology)

Abstract

:
Objective: To assess the impact of changing the reporting threshold policy of positive urine cultures in hospitalized non-pregnant adults from 104 CFU/mL to 105 CFU/mL on the unwarranted use of antibiotics and patient safety. Setting: A 1100-bed tertiary-care hospital in southern Israel. Methods: As an intervention, we changed urine culture reporting policy for patients admitted to general medical wards. If culture grew ≥105 CFU/mL, it was reported with pathogen and antibiotic susceptibility data, if it grew ≤104 CFU/mL, it was reported as “low growth". The withheld information was available upon request. We retrospectively collected data on all patients in a four-month period following the intervention and report using STROBE guidelines. Results: 7808 patients were admitted, in whom 3523 urine cultures were obtained. A total of 496 grew a pathogen, 51 were excluded (candida spp. positive, history of urinary surgery, obtained from catheter). A total of 300 were reported as positive and 145 were reported as low-growth. A higher rate of patients in the low-growth group were not treated with antibiotics 45/145(31%) vs. 56/300(18.7%) in the positive group p = 0.015 and the antibiotic duration of treatment was shorter by day 5 (IQR 0.9) vs. 6 (IQR 0.9) p = 0.015. No between-group difference was observed in recurrent admission rates, pyelonephritis within 30 days, bacteremia or all-cause mortality. Conclusions: Changing the reporting threshold of positive urine culture results from 104 CFU/mL to 105 CFU/mL in hospitalized patients reduced the number of patients who were unnecessarily treated for asymptomatic bacteriuria without negatively impacting patient safety. We urge microbiological laboratories to consider this change in threshold as part of an antimicrobial stewardship program.

1. Introduction

1.1. Background Rationale

Urinary tract infection (UTI) is the most common and over-diagnosed bacterial infection in adults [1]. Asymptomatic bacteriuria (ASBU) is frequent in older adults, both in the community and in health care institutions. The prevalence of ASBU ranges from 2% to 10% in the community and can be as high as 40–50% in long-term care facilities [1]. The presence of a positive urine culture even when a different diagnosis is considered (infectious or non-infectious) creates a challenging diagnostic dilemma for clinicians and frequently leads to an increased prescription of antimicrobials, particularly among patients who have a fever from a different cause [2].
The identification of a pathogen causing a urinary tract infection is important, as it can assist in guiding and narrowing antibiotic therapy. Culturing a suprapubic aspiration is considered the gold-standard for diagnosing UTI, where any number bacteria-forming units is considered pathogenic; however, it is rarely performed in clinical practice, especially in the adult population [3]. Obtaining a clean catch of midstream urine after cleansing of the first urine of the day is considered an appropriate alternative and is the most common method of acquiring urine culture in adult population [4]. In reality, most urine cultures are performed whenever patients approach medical services and many are performed without cleansing or proper technique, leading to a certain degree of artifactual contamination [5,6].
The standard threshold for bacterial growth on a properly collected urine sample that is considered to represent true bladder bacteriuria is ≥105 colony-forming units (CFU)/mL. (17) This threshold has been challenged and it has been recognized that, in certain conditions, a lower threshold is appropriate, especially if patients were pretreated with antibiotics [2,7,8,9,10]. This led the value of cultures that are reported as positive being lowered to 104 CFU/mL, which, in turn, led to an increase in the number of positive urine cultures, but may lead to overdiagnosis of ASBU [2,10,11]. In recent years, due to a growing concern regarding teh emergence of antimicrobial resistance secondary to increased antibiotic stress and unnecessary treatment of ASBU, it has been suggested to increase the threshold back to 105 CFU/mL [2,11,12].

1.2. Objectives

We hypothesized that changing the reporting threshold policy of positive urine cultures in hospitalized non-pregnant adults from 104 CFU/mL to 105 CFU/mL will result in a reduction in unwarranted antibiotics’ usage, especially in those with ASBU, without compromising patient safety.

2. Methods

2.1. Design

This is a retrospective study collecting data on all patients admitted to the general medicine wards of Soroka University Medical Center (SUMC) between August and November 2017. We compared the patients in whom the urine culture grew 104 CFU/mL and were reported as “low growth” without a specific pathogen or antibiotic sensitivity pattern to urine cultures that grew 105 CFU/mL and were reported as positive with pathogen identification and antibiotic sensitivity pattern. Approval and waiver of informed consent for this study was obtained from the institutional ethics committee and this report utilizes the standards for transparency reporting set by the STROBE guidelines [13].

2.2. Setting

SUMC is a 1100-bed tertiary hospital in southern Israel serving approximately one million people; it is the only hospital in a 100 km radius. Standard of care at SUMC for patients admitted with fever and those that are suspected to have an infectious process includes performing a urine culture. Urine cultures are performed in the local microbiological laboratory 5 days a week, positive cultures are identified and antimicrobial susceptibilities determined using VITEK 2 bioMérieux Clinical Diagnostics, all according to CLSI standards [14]. Final results are electronically reported through the patients electronic medical record.

2.3. Participants

Our protocol included all adults (≥18 years old) patients who were admitted to SUMC general medicine wards between August and November 2017 who grew a positive urine culture for a single bacterial pathogen. We excluded all patients in whom the urine was obtained from a urine catheter, nephrostomy tubes, polymicrobial culture, as well as pregnant patients and those with a history of urinary tract surgery; in these patients, the laboratory reported all pathogens and sensitivity data regardless of CFU/mL count.

2.4. Intervention

Starting July 2017, all positive urine culture results of patients admitted to general medical wards were reported in one of two ways: cultures that grew at least 105 CFU/mL were reported in the regular manner including the pathogen name and antimicrobial susceptibility pattern; cultures that grew 104 CFU/mL or less were reported as “positive low growth”, without the pathogens name or susceptibility pattern. The withheld information was available to the medical staff upon request.

2.5. Data

We collected data on all patients who had a positive urine culture for a four-month period following initiation of the intervention. Data were collected by manually reviewing the patient’s electronic medical records and recording all data on the hospitalization in which the positive culture grew, as well as a 90-day follow-up period.

2.6. Outcomes

Definitions of outcomes can be found in Table 1; the outcomes included both microbiological failures determined as repeat urine culture or bacteremia with the same pathogen within 30 days. Other outcomes included all-cause mortality, readmission within 30 days, and treatment with antibiotics and C. difficle.

2.7. Statistical Methods

Our primary aim in this study was to compare antibiotic usage and duration in adult, non-pregnant, hospitalized population in SUMC before and after the implementation of laboratory threshold changes to reporting a positive urine culture. Sample size calculations for this study are provided in the supplementary section. Continuous variables are presented as means ± standard deviations or as medians (interquartile ranges) as appropriate. Categorical variables are presented as percentages. Comparisons between groups were performed using independent t-test or Mann–Whitney test for continuous variables, as appropriate, and Chi-square test for categorical variables. A p-value ≤ 0.05 was considered statistically significant. All analyses were performed using SPSS version 21 (IBM, Chicago, IL, USA).

3. Results

Between August and November 2017, 7808 patients were admitted to the general medical wards; in those patients, 3523 (45.1%) urine cultures were collected, of which 496 (14.1%) were positive, 51 were excluded as they were samples from urine catheters, patients with a history of urinary surgery or grew candida. Of the 445 remaining cultures, 300 were reported as a positive urine culture (RP) with the identification of pathogen and antibiotic sensitivities, and 145 were reported only as low growth (LG); pathogen identification and susceptibly patterns withheld and reported upon request. (Figure 1) Baseline patient characteristics are shown in Table 2; no statistically significant differences were observed between the groups. A high rate of diabetes (~30%) was observed in both cohorts as well as high rates of chronic renal failure (17%). About half of the patients presented with fever and leukocytosis. In the RP group, 17 patients (5.7%) presented with hypotension, of which 16 had bacteremia congruent with and similar to their reported bacteriuria. In the LG group, 11 (7.7%) presented with hypotension, 6 of which had bacteremia congruent with and similar to their reported bacteriuria. Microbiological data on the urine cultures are presented in Table 3. The majority of identified urinary pathogens were gram-negative enteric; higher rates of enterococcus were observed in the LG group as compared to the RP [19 (13%) vs. 12 (4%), p < 0.001, as well as pseudomonas, with 13 (9%) vs. 12 (4%) p = 0.028, respectively.
The empirical antibiotics treatment rates were high in both PG and LG groups; however, they were significantly higher in the PG group, 244/300(81.3%) and 100/145(69%) p = 0.015, respectively. Comparing the non-treated patients in both groups (56 vs. 45 pts) the recurrent hospitalization rates tended to be higher but not significant in the 105 group 7 (12.5%) vs. 1 (2.2%) p = 0.057, and no difference was found in the recurrent bacteremia rates 6 (10.7%) vs. 4 (8.8%) p = 0.756 or in the mortality rates 5 (8.9%) vs. 3 (6.6%) p = 0.418 (Table 4).
The antibiotic duration of treatment was shorter by a day 5 (IQR 0.9) and 6 (IQR 0.9) in the LG and PG groups: respectively p = 0.015. No between-group difference was observed in recurrent admission rates, pyelonephritis within 30 days, bacteremia or all-cause mortality (Table 5). All deaths observed in these cohorts occurred in the sentinel hospitalization. In both groups, none of the patients who did not receive antibiotics died or developed complications such as pyelonephritis, bacteremia or recurrent admission. In the LG group, no patient suffered from pyelonephritis. One patient had bacteremia within 30 days, which was from a different pathogen determined to be not of urinary origin. Of the patients with a recurrent growth in urine culture 6 had the same pathogen and 4 presented with a different pathogen growth.

4. Discussion

Asymptomatic bacteriuria is well-known to be one of the drivers of unnecessary antibiotic therapy in patients. The threshold for reporting positive urine cultures was historically set at 105 CFU/mL. Due to concerns regarding the underdiagnosis of UTI, especially in partially treated outpatient women, many laboratories lowered their reporting threshold to 104 CFU/mL several years ago [4,15]. It was recently suggested that increasing the reporting threshold to 105 will reduce unnecessary antibiotic treatment [11,12]. This intervention was set in place as part of a hospital-wide antibiotic stewardship program, which included other interventions, and we aimed to assess the impact and safety of this. In our cohort, only 50% of the patients had fever or objective signs of an infection; thus, in about 50% of the patients, a urine culture was performed due to either clinical suspicion of an infection or for unclear reasons. We found a high rate of antibiotic usage in both groups (81.3% and 69%). The physician’s decision to start antibiotics was primarily based on clinical presentation rather than culture results. Examining the RP group, 56 patients (18.7%) were not treated with antibiotics and the urine culture was deemed to be ASBU by the clinicians; this rate improved in the LG group to 45 patients (31%). We observe that changing the threshold for reporting helped clinicians to avoid unnecessary antibiotic therapy. A urine culture reported as positive, including the pathogen name and susceptibility pattern, is a strong influence on clinicians, forcing them to reconsider their diagnosis and determine that the patient has ASBU to withhold antibiotics. In the LG cohort, where the report was of a low growth without pathogen identification or susceptibility data, the percentage of patients determined to have ASBU increased; thus, the lack of information assisted the clinicians in determining that this was an ASBU without the need for antibiotic therapy.
Our cohort included only hospitalized patients, many of whom had significant comorbidities and were admitted to acute medical care wards. All patients suspected of having an active infection were started on antibiotics prior to culture results. The antibiotics were adjusted as required according to the culture results in both groups, as microbiological data was available upon demand to clinicians in the LG group. This fact helps to exclude patients with ASBU and increase the safety of the intervention. When analyzing patients who were not treated with antibiotics in both groups, which could either represent ASBU or an occult infection, none developed pyelonephritis, became bacteremic or died. These results are similar to previously published interventions of a pilot study performed by leis and colleagues [11]. When a clinician chooses to perform a urine culture without starting empiric antibiotics, his assessment of a pretest probability for infection is low, thus withholding empiric antibiotic therapy. A positive urine test result may alter this decision; however, we have shown that patients in the LG group were not adversely affected by the change in the reporting threshold. To strengthen this concept, a prospective randomized control trial, focused on the outcome of non-treated patients in both groups, is still needed.
The pathogens identified in both groups were mostly gram-negative enteric pathogens as is expected; however, we did see a larger percentage of Enterococcus spp. in the cultures that grew 104 CFU/mL. This observation is similar to a previous report by Hooton and colleagues [4]. Enterococcus spp. Urine with low counts is considered to be of lower virulence and is usually not covered by empiric antibiotic therapy for urinary tract infection [16]. Our study demonstrated that, even though we observed a large percentage of untreated Enterococcus spp., we did not observe higher failure or recurrence rates in these patients.
There are several limitations to this study. Yhe first and foremost is its retrospective nature; this limits the available clinical information on these patients, and precludes understanding of the reasoning behind some of the urine cultures that were obtained. We do not have data regarding how often the physician in the LG group asked for full bacteriological results and antibiotic sensitivity. We have limited data on antibiotics taken prior to admission, and thus cannot discuss the impact of prior antibiotic therapy on culture results.

5. Conclusions

Changing the reporting threshold of positive urine culture results from 104 CFU/ml to 105 CFU/ml on hospitalized patients may reduce the number of unnecessarily treated patients for asymptomatic bacteriuria without negatively impacting patient safety. We urge microbiological laboratories to consider this change in threshold as part of an antimicrobial stewardship program.

Author Contributions

Conceptualization, O.G. and L.N.; methodology, G.T.; software, G.T.; formal analysis, O.G.; investigation, O.G., T.C. and Y.B.; writing—original draft preparation, O.G.; writing—review and editing, O.G.; visualization, O.G.; supervision, L.N.; All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

The research was approved by the Institutional Review Board (“Helsinki committee”) for Research Management in Soroka medical center, approval code 0356-SOR 17.

Informed Consent Statement

Patient consent was waived due to the retrospective nature of the study and analysis used anonymous clinical data.

Data Availability Statement

The data presented in this study are available on request from the corresponding author. The data are not publicly available due to institutional restrictions.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Mody, L.; Riddell, J.; Kaye, K.S.; Chopra, T. Common Infections. In Current Diagnosis & Treatment: Geriatrics, 2nd ed.; Williams, B.A., Chang, A., Ahalt, C., Chen, H., Conant, R., Landefeld, C.S., Ritchie, C., Yukawa, M., Eds.; McGraw-Hill Education: New York, NY, USA, 2014. [Google Scholar]
  2. Nicolle, L.E.; Gupta, K.; Bradley, S.F.; Colgan, R.; DeMuri, G.P.; Drekonja, D.; Eckert, L.O.; Geerlings, S.E.; Köves, B.; Hooton, T.M.; et al. Clinical Practice Guideline for the Management of Asymptomatic Bacteriuria: 2019 Update by the Infectious Diseases Society of Americaa. Clin. Infect. Dis. 2019, 68, e83–e110. [Google Scholar] [CrossRef] [PubMed]
  3. Bailey, R.R.; Little, P.J. Suprapubic Bladder Aspiration in Diagnosis of Urinary Tract Infection. BMJ 1969, 1, 293–294. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  4. Hooton, T.M.; Roberts, P.L.; Cox, M.E.; Stapleton, A.E. Voided Midstream Urine Culture and Acute Cystitis in Premenopausal Women. N. Engl. J. Med. 2013, 369, 1883–1891. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  5. LaRocco, M.T.; Franek, J.; Leibach, E.K.; Weissfeld, A.S.; Kraft, C.S.; Sautter, R.L.; Baselski, V.; Rodahl, D.; Peterson, E.J.; Cornish, N.E. Effectiveness of Preanalytic Practices on Contamination and Diagnostic Accuracy of Urine Cultures: A Laboratory Medicine Best Practices Systematic Review and Meta-analysis. Clin. Microbiol. Rev. 2016, 29, 105–147. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  6. Wilson, M.L.; Gaido, L. Laboratory Diagnosis of Urinary Tract Infections in Adult Patients. Clin. Infect. Dis. 2004, 38, 1150–1158. [Google Scholar] [CrossRef] [Green Version]
  7. Kass, E.H. Asymptomatic infections of the urinary tract. Trans. Assoc. Am. Physicians 1956, 69, 56–64. [Google Scholar] [PubMed]
  8. Platt, R. Quantitative definition of bacteriuria. Am. J. Med. 1983, 75, 44–52. [Google Scholar] [CrossRef] [PubMed]
  9. Kunin, C.M.; White, L.V.; Hua, T.H. A Reassessment of the Importance of Low-Count Bacteriuria in Young Women with Acute Urinary Symptoms. Ann. Intern. Med. 1993, 119, 454–460. [Google Scholar] [CrossRef] [PubMed]
  10. Kwon, J.H.; Fausone, M.K.; Du, H.; Robicsek, A.; Peterson, L.R. Impact of laboratory-reported urine culture colony counts on the diagnosis and treatment of urinary tract infection for hospitalized patients. Am. J. Clin. Pathol. 2012, 137, 778–784. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  11. Smith, M.-A.; Lamb, M.J.; Baillie, L.; Simor, A.; Leis, J.A. Clinical Significance of Low Colony-Count Urine Cultures Among Hospitalized Inpatients. Infect. Control Hosp. Epidemiol. 2018, 39, 488–489. [Google Scholar] [CrossRef] [PubMed]
  12. Leis, J.A.; Rebick, G.; Daneman, N.; Gold, W.L.; Poutanen, S.; Lo, P.; Larocque, M.; Shojania, K.G.; McGeer, A. Reducing Antimicrobial Therapy for Asymptomatic Bacteriuria Among Noncatheterized Inpatients: A Proof-of-Concept Study. Clin. Infect. Dis. 2014, 58, 980–983. [Google Scholar] [CrossRef] [PubMed]
  13. Tacconelli, E.; Cataldo, A.M.; Paul, M.; Leibovici, L.; Kluytmans, J.; Schröder, W.; Foschi, F.; De Angelis, G.; De Waure, C.; Cadeddu, C.; et al. STROBE-AMS: Recommendations to optimise reporting of epidemiological studies on antimicrobial resistance and informing improvement in antimicrobial stewardship. BMJ Open 2016, 6, e010134. [Google Scholar] [CrossRef]
  14. CLSI. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing an Informational Supplement for Global Application Developed through the Clinical and Laboratory Standards Institute Consensus Process, 26th ed.; Clinical and Laboratory Standards Institute: Wayne, PA, USA, 2016. [Google Scholar]
  15. Stamm, W.E.; Wagner, K.F.; Amsel, R.; Alexander, E.R.; Turck, M.; Counts, G.W.; Holmes, K.K. Causes of the Acute Urethral Syndrome in Women. N. Engl. J. Med. 1980, 303, 409–415. [Google Scholar] [CrossRef] [PubMed]
  16. Gupta, K.; Hooton, T.M.; Naber, K.G.; Wullt, B.; Colgan, R.; Miller, L.G.; Moran, G.J.; Nicolle, L.E.; Raz, R.; Schaeffer, A.J.; et al. International Clinical Practice Guidelines for the Treatment of Acute Uncomplicated Cystitis and Pyelonephritis in Women: A 2010 Update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin. Infect. Dis. 2011, 52, e103–e120. [Google Scholar] [CrossRef]
Figure 1. Flow chart of patients included in the study cohort who were admitted to the General Medical wards during a four-month period following an intervention to urine culture report policy.
Figure 1. Flow chart of patients included in the study cohort who were admitted to the General Medical wards during a four-month period following an intervention to urine culture report policy.
Jcm 11 07014 g001
Table 1. Definition of outcomes for the intervention.
Table 1. Definition of outcomes for the intervention.
Admission DurationLength of Hospitalization in Which the Positive Urine Culture Was Identified
No antibiotics therapyPatients in whom no antibiotic therapy was provided during the hospitalization or recommended on discharge
Antibiotic therapy durationLength of antibiotic therapy during hospitalization
Recurrent admission 30 dayPatients who were readmitted for any cause within 30 days
positive urine culture 90-day same pathogenA positive urine culture obtained within 90 days of the original culture and grew the same pathogen as the original culture
positive urine culture 90-day different pathogenA positive urine culture obtained within 90 days of the original culture and grew a different from the original culture
Bacteremia within 30 dayBacteremia within 30 days of the same pathogen that grew in the original urine culture
Mortality all cause 90 dayAll-cause mortality within 90 days
C. difficilePatients who developed C. difficle infection within 3 months of the positive culture
Table 2. Baseline patient characteristics comparing patients with urine culture that were reported as low growth to patients that were reported as positive.
Table 2. Baseline patient characteristics comparing patients with urine culture that were reported as low growth to patients that were reported as positive.
Reported Low Growth n = 145
n (%)
Reported Positive n = 300
n (%)
p Value
Gender female97 (68.3)217 (72.3)0.384
Age (standard deviation)58 ± 2359 ± 240.578
Diabetes mellitus45 (31.7)91 (30.3)0.773
Chronic renal failure25 (17.6)52 (17.3)0.944
Congestive heart failure8 (5.6)25 (8.3)0.313
Chronic heart disease18 (12.7)49 (16.3)0.317
Chronic lung disease11 (7.7)12 (4)0.098
History of Stroke11 (7.7)27 (9)0.661
Charleston comorbidity score Median (IQR 25.75)1 (0.3)1 (0.3)0.931
Fever > 38.267 (47.2)155 (51.7)0.379
Presented with Hypotension MAP < 7011 (7.7)17 (5.7)0.402
Presented with WBC > 10,00065 (45.8)131 (43.7)0.677
Bacteremia on presentation same pathogen as urine6 (4.1)16 (5.3)0.649
Bacteremia on presentation different pathogen1(0.6)3 (1%)0.998
Table 3. Microbiological data of urine cultures comparing cultures reported as low growth to those reported as positive.
Table 3. Microbiological data of urine cultures comparing cultures reported as low growth to those reported as positive.
Reported Low Growth n = 145
n (%)
Reported Positive n = 300
n (%)
p Value
Escherichia coli84 (58)192 (64)0.128
Klebsiella spp.17 (12)57 (19)0.057
Enterococcus spp.19 (13)12 (4)<0.001
Pseudomonas aeruginosa13 (9)12 (4)0.028
Proteus mirabilis8 (6)16 (5)0.999
Morganella morganii4 (2)11 (4)0.999
Table 4. Comparison of the antibiotic treatment rates on low-growth vs. positive-growth group and hard outcome of untreated patients in both groups.
Table 4. Comparison of the antibiotic treatment rates on low-growth vs. positive-growth group and hard outcome of untreated patients in both groups.
LOW Growth (%)Positive Growth (%)
Antibiotic treatment100(69%)244(81.3%)p = 0.015
Not treated45(31%)56(18.7%)p = 0.015
Not treated
recurrent hospitalization
1(2.2%)7(12.5%)p = 0.057
Not treated
Bacteremia within 30 d
4(8.8%)6(10.7%)p = 0.756
Not treated
mortality
3(6.6%)5(8.9%)p = 0.418
Table 5. Comparison of patient outcomes with urine cultures that were reported as low growth to patients that were reported as positive.
Table 5. Comparison of patient outcomes with urine cultures that were reported as low growth to patients that were reported as positive.
Reported Low Growth n = 145
n (%)
Reported Positive n = 300
n (%)
p Value
Admission duration median (IQR 25.75)3 (0.7)3 (0.6)0.879
No antibiotics therapy45 (31)56 (18.7)0.015
Antibiotic therapy duration median (IQR 25.75)5 (0.9)6 (0.9)0.015
Recurrent admission 30 day18 (12.7)39 (13)0.924
Pyelonephritis within 30 day0 (0)3 (1)0.764
Positive urine culture 90-day same pathogen6 (4.2)12 (4)1
Positive urine culture 90-day different pathogen4 (2.7)10 (3.3)0.785
Bacteremia within 30 day1 (0.6)2 (0.7)0.507
Mortality all cause 90 day8 (5.6)22 (7.3)0.507
C. difficle0 (0)0 (0)
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Gabay, O.; Cherki, T.; Tsaban, G.; Bichovsky, Y.; Nesher, L. The Safety and Impact of Raising the Urine Culture Reporting Threshold in Hospitalized Patients. J. Clin. Med. 2022, 11, 7014. https://doi.org/10.3390/jcm11237014

AMA Style

Gabay O, Cherki T, Tsaban G, Bichovsky Y, Nesher L. The Safety and Impact of Raising the Urine Culture Reporting Threshold in Hospitalized Patients. Journal of Clinical Medicine. 2022; 11(23):7014. https://doi.org/10.3390/jcm11237014

Chicago/Turabian Style

Gabay, Ohad, Tal Cherki, Gal Tsaban, Yoav Bichovsky, and Lior Nesher. 2022. "The Safety and Impact of Raising the Urine Culture Reporting Threshold in Hospitalized Patients" Journal of Clinical Medicine 11, no. 23: 7014. https://doi.org/10.3390/jcm11237014

APA Style

Gabay, O., Cherki, T., Tsaban, G., Bichovsky, Y., & Nesher, L. (2022). The Safety and Impact of Raising the Urine Culture Reporting Threshold in Hospitalized Patients. Journal of Clinical Medicine, 11(23), 7014. https://doi.org/10.3390/jcm11237014

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop